membrane, the contents of the cytoplasm, including lysosomal enzymes, are released into the extracellular fluid, and this results in an intense inflammatory response. Each of the major pathways of cell death needs to be considered if cell-based medicine is to become a reality in the clinical setting (32) . Interventions known to reduce apoptosis include overexpression of antiapoptotic proteins or blockade of apoptotic pathways; these mechanisms provide many possibilities for the study of methods to reduce the death of transplanted cells (6, 18) . Despite its important role in cell death, few attempts have been made to reduce necrosis; this is because of the conventional notion that, unlike apoptosis, necrosis is unregulated. However, because transplanted cells are usually exposed to extremely hostile environments, it is likely that necrosis inhibition plays a more important role in enhancing engraftment survival than apoptosis inhibition.
In the present study, whether survival factor priming could suppress transplanted cell death in vivo was investigated. In addition, whether the surviving fibroblasts embedded in the myocardium, transplanted after pretreatment, could develop subsequent fibrosis and modify conduction at a specific site were evaluated in a canine model. The results of this study could serve as a novel strategy of cell therapy as well as a new concept of bioablation that could be used to investigate new treatment strategies for arrhythmias.
METHODS

Assessment of necrosis inhibition.
The NIH 3T3 cell line (American Type Culture Collection) was used for the in vitro cell death experiment. Cells were exposed to 5 mM tert-butyl hydroperoxide (tBHP) for 100 min for the induction of necrosis and exposed to 0.3 mM etoposide for 4 h for the induction of apoptosis. Assessment of apoptosis and necrosis was performed using an annexin-V-propidium iodide (PI) staining kit (BD Pharmingen). Samples were prepared according to the manufacturer's instructions and were analyzed by flow cytometry. Annexin V-positive and PI-negative cells were regarded as apoptotic cells. Annexin V-negative and PI-positive cells were regarded as necrotic cells.
In addition to in vitro cell death experiment, we performed an in vitro intracellular duration assay by treating the cells with necrosis inhibitor (NI) according to the experimental protocol, washed them with PBS, and transferred the cells into a 37°C CO 2 incubator to measure the intracellular level of this molecule according to the time course, which was thought to be a surrogate marker of drug effect duration. Liquid chromatography-mass spectrometry was used to measure the intracellular concentration of NI.
Murine model and surgical preparation. Wild-type C57BL/6J mice [chicken ␤-actin promoter-driven ubiquitous green fluorescent protein (GFP)-expressing mice on a C57 background, Jackson Laboratory] were used for morphometric and quantitative analysis. All animal experiments were performed after approval was received from the Institutional Animal Care and Use Committee of the Clinical Research Institute of Seoul National University Hospital.
For the murine model, cardiac fibroblasts were isolated from the hearts of male GFP-positive mice. Primary fibroblast cultures were established as previously described (29) . Briefly, mice were anesthetized by an intraperitoneal injection of Zoletil (containing a dissociative anesthetic, tiletamine-zolazepam, at a ratio of 1:1, 25 mg/kg) plus xylazine (10 mg/kg). After a complete absence of the pedal withdrawal reflex, which reflected a good anesthetic induction, a median thoracotomy was performed. GFP-positive hearts were then harvested, sliced with a sterile scalpel, and mixed with collagenase type II at 37°C over 30 min; the cell suspension was cultured in DMEM supplemented with 10% FBS and antibiotic solution. Because fibroblasts attach to the dish and proliferate rapidly, the supernatant and media were removed from the dish with a micropipette. Media were replaced every other day to purify cardiac fibroblasts. Plated cells were assessed daily for growth. The purity of the obtained cardiac fibroblast culture was confirmed microscopically by characteristic cell morphology.
Survival factor priming and study groups. To prevent necrosis, 100 mol of a new small-molecule NI, NecroX-7 (LG Life Sciences, Daejeon, Korea), which was synthesized and developed as a NI, was introduced into the prepared fibroblast culture for 24 h before cell injection. NecroX-7 specifically inhibits necrotic cell death; however, it does not affect apoptotic and necroptotic cell death (5, 12) . Akt overexpression was also used as another survival factor priming method (4, 6, 17) . For Akt overexpression, cultured fibroblasts were transfected with Akt-contining adenoviruses at 200 multiplicities of infection for 24 h before injection of the cells (13) . For the control group, fibroblasts were transfected with ␤-galactosidase-contining adenovirus in the same manner.
Female C57BL/6 mice were assigned to receive one of three different pretreated fibroblasts: 1) fibroblasts transfected with ␤-galactosidase-containing adenovirus (control group), 2) fibroblasts treated with NI (NI group), and 3) fibroblasts transfected with Aktcontaining adenovirus (Akt group). Pretreated cells were introduced to the recipient heart after a thoracotomy. In brief, animals were anesthetized in the same manner as described above and ventilated on room air supplemented with O 2, and a left anterior thoracotomy was then performed under aseptic conditions. In the murine model, 5 ϫ 10 5 cardiac fibroblasts (0.02 ml) were prepared and injected into the anterior myocardium using a 26-gauge needle. After the cell injections, the chest wall was closed, and mice were permitted to recover in a warming chamber. Hearts were harvested at 0, 1, 3, 7, 14, and 21 days after the injection from anesthetized mice. For real-time PCR, harvested hearts were kept in a frozen state in liquid nitrogen. For morphometric analysis, hearts were fixed with 4% paraformaldehyde perfusion for 20 min and then embedded in paraffin.
Quantitative evaluation of cellular engraftment using real-time PCR. Relative quantitative real-time PCR was performed on 96-well optical plates and analyzed using an ABI Prism 7500 sequence detection system. Grafted male cells in the hearts of the female recipients were analyzed by real-time PCR to quantify the Y chromosome-specific gene [sex-determining region of chromosome Y (Sry)] at 0, 1, 3, 7, 14, and 21 days after injection of the cells, as described in previous publications (15, 20) . In brief, standard samples were obtained from serially diluted male fibroblasts (5 ϫ 10 5 , 5 ϫ 10 4 , 5 ϫ 10 3 , 5 ϫ 10 2 , and 5 ϫ 10 1 male fibroblasts) mixed with 5 ϫ 10 5 female fibroblasts. From these mixtures, genomic DNA was extracted using a Genomic DNA Extraction kit (Intron) and used to evaluate the number of grafted male fibroblasts.
Hearts harvested for the quantitative evaluation of cellular engraftment were divided and finely homogenized. The homogenized heart was efficiently lysed using lysis buffer [0.5% SDS, 50 mM Tris (pH 8.0), 10 mM NaCl, and 2 mM EDTA] and proteinase K (Sigma) at 60°C for 12 h, and DNA was extracted. Real-time PCR was then performed as described below. Sample DNA concentrations were equalized by titration, and thus equal amounts of total DNA (100 ng) were loaded during the real-time PCR procedures. For the primertargeted male-specific Sry gene, the sequences were as follows: forward, 5=-TTCCAGGAGGCACAGAGATT-3=, and reverse, 5=-GCCTGTATGTGATGGCATGT-3=. The cycling conditions were 5 min at 50°C, 10 min at 95°C for the activation of polymerase, 30 s at 95°C for denaturation, and 60 s at 60°C to induce annealing and extension.
An amplification plot (Fig. 3A) and a standard sample curve (Fig.  3B) (1)
Number of engrafted fibroblasts ϭ Male DNA amount
Total DNA amount ϫ Total number of nuclei in the heart (2) For the calculation of the absolute number of transplanted cells, in the heart, the male DNA-to-total DNA ratio obtained from real-time PCR was multiplied by the total number of nuclei in the mouse heart. To the best of our knowledge, there was no reference about the total number of nuclei in the murine heart, so we had to make several assumptions before we calculated it (15) . Although most cardiomyocytes were binucleate, we regarded them as mononucleate cells to simplify the calculation of the total heart cell count, which was only used as reference to compare the remaining male cell count. Assuming that there was no death of transplanted cells on day 0, when the heart was immediately harvested after injections of the cells, we found the ratio of the male DNA amount to the total DNA amount on day 0 using Eq. 1. With regard to the number of engrafted cells on day 0 as 5 ϫ 10 5 cells by assumption, we calculated the total number of nuclei in the heart using Eq. 2. We calculated the total number of nuclei in the heart using the mean C t value from all mice on day 0, which was 1.23 ϫ 10 8 cells. Morphometric analysis. For the morphometric analysis, Masson's trichrome staining was used. Areas with fibrosis were assessed using a digital image-analysis system (Image-Pro plus 4.5) and expressed as percent fibrosis (the ratio of the fibrotic area to the total left ventricular area). For immunofluorescent staining, unstained sections were deparaffinized and processed as previously described (13) . Anti-GFP (Santa Cruz Biotechnology), anti-vimentin (Santa Cruz Biotechnology), and anti-␣-smooth muscle actin (␣-SMA; Abcam) were then added. Antirabbit IgG-Alexa fluor 488 (Invitrogen), anti-goat IgG-Alexa fluor 555 (Invitrogen), anti-mouse IgG-Alexa fluor 647 (Invitrogen), and anti-rabbit IgG horseradish peroxidase-conjugated antibody (Promega) were used for signal detection. Nuclei were stained with SYTOX blue (Invitrogen). Specimens were evaluated using a confocal microscope (LSM7, Carl Zeiss). For immunohistochemical staining, CD11b (Cell Signaling) was used.
Canine model and surgical preparation to evaluate conduction delay. For the assessment of conduction delay, nine adult male mongrel dogs (weight: 15-20 kg) were studied. Animal experiments were performed under National Institutes of Health guidelines, and the study protocol was approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital. Following standard and approved protocols, all dogs were anesthetized with thiopental (20 mg/kg iv), intubated, and mechanically ventilated followed by gaseous anesthesia (1-2% isofluorane-O 2). All measures were taken to ensure that discomfort, distress, pain, and injury were limited to that which was unavoidable. Standard surface ECG leads were monitored continuously throughout the entire study. Intermittent arterial blood gas measurements were obtained, and ventilator adjustments were made to correct for any metabolic abnormalities. An electrical heating pad was used to maintain body temperature at 36 -37°C. Dogs were randomly divided into the following three groups, similar to the murine model: control, NI, and Akt groups. Autologous fibroblasts were used and harvested from the dermis of each dog assigned to cell therapy. The preparation and culturing methods of the dermal autologous fibroblasts were simply described as below: a skin specimen (ϳ2 ϫ 2 cm) was harvested from right shoulder of each dog assigned to receive a cell-based therapy and immediately placed in culture media containing DMEM with 10% FBS and antibiotic solution. The epidermis and underlying connective tissue (such as fat) were dissected from specimen, and the tissue was sliced with a sterile scalpel and mixed in 10 ml of 0.25% trypsin at 37°C for 15 min. The fluid was then withdrawn with a pipette and placed in the culture media containing BSA to stop digestion. This process was repeated after the addition of 10 ml of 0.25% trypsin to the skin specimen until the solution no longer became cloudy after 15 min of exposure. Dissociated cells were placed in culture media and plated for culture. Media were replaced every other day thereafter.
To induce conduction delay in the canine heart, 1 ϫ 10 6 (0.2 ml) autologous fibroblasts/site were injected into the left anterior ventricular epicardial wall after a left lateral thoracotomy was performed. Ten total injections were made at 1.0-to 1.5-mm intervals in a line. The maximal injection depth was 5 mm to avoid wall perforation and loss of the cells. The conduction time was measured on day 0 and 4 wk after the injection of cells. Conventional catheters consisting of pacing and recording electrodes were used; the distance between the two electrodes was 10 mm. Pacing with a pulse width of 1 ms and an amplitude of two times the threshold was performed at a cycle length of 250 -300 ms. For euthanasia, ventricular fibrillation was induced by KCl injection under anesthesia.
Statistical analysis. All data are expressed as means Ϯ SD. MannWhitney tests, one-way ANOVA, and Kruskal-Wallis tests were used to determine significant differences among the groups. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Effect of NI.
First, we examined whether NI (NecroX-7) truly reduced cell death. To induce necrotic cell death, we incubated NIH 3T3 cells with 5 mM tBHP for 100 min (8) . In the vehicle-treated control group, cellular necrosis reached up to 42%. Akt or Z-VAD-fmk (a caspase inhibitor) treatments did not significantly alter necrosis fraction. In contrast, NI treatment significantly decreased cellular necrosis by 7.0% (Fig. 1A) . To induce apoptotic cell death, we incubated cells with 0.3 mM etoposide for 4 h (16). The control group showed 40.3% of the cells in the early apoptosis state and 6.5% of the cells in the late apoptosis state. Akt or Z-VAD-fmk treatments significantly reduced apoptosis compared with the control group. However, NI treatment did not affect apoptotic cell Fig. 1 . Effects of necrosis inhibition and Akt overexpression on cell death. NIH 3T3 cells were exposed to 5 mM tert-butyl hydroperoxide (tBHP) for the induction of necrosis and exposed to 0.3 mM etoposide for the induction of apoptosis. Z-VAD-fmk (caspase inhibitor) was used as a positive control. A: the necrotic cell fraction was significantly reduced in the necrosis inhibitor (NI) group compared with the control group (7% vs. 42%). B: Akt overexpression (Akt group) reduced apoptotic cell death. The rate of early apoptotic cell death in the Akt group was 11.3%, which was lower than in the control group by 30%. The rate of apoptotic cell death in the NI group was similar to that of the control group (early apoptosis: 37.1% vs. 40.3% and late apoptosis: 8.0% vs. 6.5%). death (Fig. 1B) . Taken together, these results indicated that NI reduced cell death mainly by inhibiting necrosis.
Second, we measure the intracellular concentration of NI to clarify the intracellular persistence of this molecule, which was thought to be a surrogate marker of NI effect duration. We demonstrated that 90% of NI disappeared within a few minutes, and ϳ5% of this molecule resided in the cells for Ͼ24 h (Table 1) . We suggest that a small amount of NI could be localized into the mitochondria and endoplasmic reticulum, resulting in the cytoprotective effect against necrotic/hypoxic injury.
Survival factor priming enhanced the efficiency of cell engraftment. We checked the purity and phenotype of cultured fibroblasts before priming and injection. To prove the purity of the obtained fibroblast culture, we checked whether cells expressed vimentin and did not exhibit stem cell and endothelial cell characteristics (Fig. 2A) . For phenotype confirmation, we checked ␣-SMA expression (Fig. 2B) . Cultured fibroblasts per se before injection did not exhibit ␣-SMA but exhibited ␣-SMA under specific stimulation, such as with transforming growth factor (TGF)-␤. This indicated that the culture did not result in a phenotype change before survival factor priming and injection.
Whether survival factor priming could enhance cellular engraftment in vivo in the murine model was then investigated by quantifying engrafted male cardiac fibroblasts.
The engrafted cell count was similar in all three groups on day 0. However, this number rapidly dropped and further declined to 0. For the Akt group, the number of engrafted cells was also greater than the control group after day 14; this difference was statistically significant (Fig. 3C and Table 2 ). The engraftment rate in the NI group was about two times greater than in the Akt group on day 7 (93,289 Ϯ 18,754 vs. 39,566 Ϯ 12,806 cells, P Ͻ 0.05) and day 21 (6,964 Ϯ 1,682 vs. 3,949 Ϯ 211 cells, P Ͻ 0.05). These results indicated that survival factor priming significantly enhanced the efficiency of cell engraftment. In addition, NI was superior to Akt overexpression in regard to cellular engraftment.
Engrafted fibroblasts contributed to the development of fibrosis. To evaluate the fate of the engrafted cells, immunofluorescent staining with anti-GFP, anti-vimentin, and anti-␣-SMA was performed. The injected fibroblasts were positive for GFP and vimentin. The engrafted fibroblasts (GFP positive/ vimentin positive) remained at the injection site on day 7 in the NI and Akt groups (Fig. 4) . However, other types of fibroblasts (GFP negative/vimentin positive) were also noted around the engrafted cells. ␣-SMA, a marker for differentiated myofibroblasts involved in the development of fibrosis, was positive in some of the GFP-positive/vimentin-positive and GFP-negative/vimentin-positive fibroblasts on day 7. These results suggested that the engrafted fibroblasts directly contributed to the development of fibrosis by differentiation to myofibroblasts at the injection site and indirectly by recruiting other types of host fibroblasts that may, in part, be related to paracrine effects.
Survival factor priming increased the area of fibrosis. Morphometric analysis was performed to investigate whether survival factor priming could enhance cellular engraftment and induce substantial fibrosis in an in vivo murine model. In the NI and Akt groups, the engrafted cells in the heart were greater in number than in the control group at all times. In addition, fibrosis was more apparent by day 21 (Fig. 5A) . However, in the control group, the number of injected fibroblasts appeared to be less than in the other groups on day 3. In addition, injected cells and fibrosis were nearly absent after day 7. When the area of fibrosis was measured by image-analysis software (Fig. 5B ), the NI group had an increase in the area of percent fibrosis compared with the control group (6.88 Ϯ 1.42% vs. 0.18 Ϯ 0.27%, P ϭ 0.003). The Akt group also had increased areas of fibrosis compared with the control group (6.61 Ϯ 1.02% vs. 0.18 Ϯ 0.27%, P ϭ 0.003). There were no significant differences between the NI and Akt groups (P ϭ 0.873). Taken together, these results demonstrated that survival factor priming induced substantial fibrosis in vivo by enhancing cellular engraftment. In regard to the induction of fibrosis in the in vivo murine model, the effect of NI was similar to Akt overexpression.
To evaluate whether increased fibrosis is associated with inflammation, we performed immunohistochemical staining using CD11b antibody (a pan-leukocyte marker). As shown Fig. 5C , the more engrafted fibroblasts that remained, the more inflammatory cells that infiltrated around them. This was nearly absent in the control group on day 7. These results suggested that engrafted fibroblasts might have the potential to recruit inflammatory cells and intensify or prolong inflammation in a paracrine manner, which led to increased fibrosis.
Engrafted fibroblasts resulted in conduction delay in the canine model. The NI and Akt groups showed discrete areas of fibrosis at the injection sites (Fig. 6A ). Significant fibrosis was not observed in the control group. The conduction time was measured as the time interval between the pacing and recording electrodes around the injection sites in the canine heart (Fig. 6,  B and C) . The baseline conduction time was similar in the NI, Akt, and control groups (22.3 Ϯ 3.21 vs. 20.7 Ϯ 4.04 vs. 22.3 Ϯ 2.08 ms). At 4 wk, the NI group showed significantly prolonged conduction time than the control group (41.7 Ϯ 6.66 vs. 23.7 Ϯ 1.15 ms, P ϭ 0.046), and there were changes of the activation sequence indicating conduction block at the injection site (Fig. 6B) . The conduction time of the Akt group (35.3 Ϯ 10.1 ms) showed insignificant prolongation compared with the control group. These results indicated that delivery of fibroblasts, primed with survival factors, might be able to induce fibrosis and conduction delay in the heart of this animal model.
DISCUSSION
One of the most important issues in the cell therapy field is enhancement of cellular engraftment by reducing death of transplanted cells. In the present study, we studied 1) whether survival factor priming improves the survival of transplanted fibroblasts in the heart and 2) whether increased fibroblast engraftment induces more fibrosis. The results demonstrated that the engraftment rate of the fibroblasts and percent area of fibrosis were much greater in the NI and Akt groups than in the control group in the murine model using morphometric analysis and quantitative real-time PCR. In addition, whether pretreated fibroblasts were involved in the development of fibrosis and induced conduction delay were studied in a canine model. Four weeks after the injection of cells, fibrosis and conduction delay were significant in the NI group compared with the control group. Thus, delivery of fibroblasts primed with survival factors might be a promising approach for conduction modification of the heart. Consistent with previous studies (20, 21, 30) , the number of remaining transplanted fibroblasts was very low in the control group; it was 19% on day 3, 4.71% on day 7, and 0.1% by day 21. This poor cell survival was likely caused by multiple processes, such as anoikis due to detachment from the sub- strate, ischemia, and inflammation. The cells lost survival signals with matrix detachment, and ischemia induced ATP depletion and intracellular Ca 2ϩ dysregulation, which resulted in mitochondrial cytochrome c release, inducing cell death (10, 32) . Free radicals produced under ischemia and inflammatory condition cause fatal cell membrane damage (19) . Therefore, for cell-based medicine to be effective in the clinical setting, the prevention of cell death must be addressed (26) . NecroX-7 was used as a NI, which has mitochondrial ROS scavenging effects and prevents cell damage (5, 12) .
As shown in Fig. 3 and Table 2 , necrosis inhibition increased the engraftment rate; it was ϳ13 times greater than in the control group by day 14. The engraftment rate in the NI group was about two times greater than in the Akt group on days 7 and 21. Although the study of reducing necrosis has been limited, because of the conventional notion that necrosis is unregulated, unlike apoptosis, it appears that necrosis inhibition plays an important role in enhancing engraftment survival. According to the results of the in vitro intracellular duration assay, we assumed that the cell containing the small amounts of NI could provide a survival signal for a few days (at least 1 day), indicating a transient effect of NI for cell survival after in vivo cell implantation. Considering the facts that most of the engrafted cell death occurred within a few days in the hostile environment and that cells protected from initial injury could survive for a long time by settling into their new environment, the protective effect of NI could have a great role in enhancing engraftment efficiency, although it was transient.
In the canine model, conduction delay was observed in the NI and Akt groups by 4 wk after fibroblast injection. However, Fig. 3 . Quantification of transplanted fibroblasts by DNA copy number using real-time PCR. A: amplification plot of quantitative real-time PCR using standard male/female fibroblast DNA dilutions. Threshold cycles (Ct) increased by ϳ3 when the dilution of male DNA was increased 10-fold. A primer against the male-specific sex-determining region of chromosome Y (Sry) gene was used. B: standard calibration curve from known male DNA/total DNA dilution (x-axis) and Ct value (y-axis). Values were plotted on a double logarithmic scale to obtain a balanced contribution for all reference dilutions (correlation coefficient: 0.953). C: real-time PCR showing that necrosis inhibition and Akt overexpression significantly enhanced the rate of engraftment. The engraftment rate in the NI group was 13 times greater than in the control group by day 21. In the Akt group, the engraftment rate was 7 times greater than in the control group by day 21. Values are shown in Table 2 . (Fibroblasts transfected with ␤-galactosidase-containing adenovirus were the control group, fibroblasts treated with NI were the NI group, and fibroblasts transfected with Akt-containing adenovirus were the Akt group.) there was no conduction delay in the control group. Failure to develop enough fibrosis to produce conduction delay in the control group might have been due to the early death of transplanted cells and the resulting poor extracellular matrix deposition.
As shown in Fig. 4 , some injected fibroblasts (GFP positive/ vimentin positive) remained at the injection site and expressed ␣-SMA by 7 days. There were many other fibroblasts (GFP negative/vimentin positive) around the injected fibroblasts (GFP positive/vimentin positive). Some of them also expressed ␣-SMA. These results show that the injected fibroblast not only produced nonconductive proteins but also served as a substrate to recruit other fibroblasts, which differentiated into myofibroblasts and contributed to the development of fibrosis. We also found that increased engraftment was associated with increased inflammation. Because fibroblasts were found to be on significant sources of several cytokines, including TGF-␤ 1 and CC chemokine in other studies (1, 23) , this result suggested that engrafted fibroblasts might have the potential to recruit inflammatory cells and intensify or prolong inflammation in a paracrine manner, which resulted in increased fibrosis. While the role of inflammation around engrafted cells was still not well understood, we thought it had positive effects with respect to engrafted cell survival and the development of fibrosis. In one study (14) , macrophages actively participated in the process of establishing a vascular network between the implanted graft and recipient vasculature, which provided a more friendly environment for engrafted cells to survive. In addition, inflammatory cells are known to produce several important cytokines tied to fibrosis, such as enrollment and phenotype transition of fibroblasts (24) .
In this study, two in vivo models were evaluated. A murine model was used for in molecular biological experi- . Cellular engraftment and subsequent fibrosis after fibroblast injection in the murine model. A: in the NI and AKT groups, the number of engrafted cells in the heart that remained were greater than in the control group at all times, and fibrosis was more apparent by day 21. Injected fibroblasts and fibrosis were nearly absent after day 7 in the control group. All samples were stained with Masson's trichrome (MT) stain. B: areas of fibrosis on day 21 were assessed using a digital pixel analyzer and expressed as percent fibrosis [ratio of the fibrotic area to the total left ventricular (LV) area]. Two samples/mouse and three mice/group were analyzed with Mann-Whitney and Kruskal-Wallis tests. The NI group had an increased percent area of fibrosis compared with the control group (6.88 Ϯ 1.42% vs. 0.18 Ϯ 0.27%, P ϭ 0.003). The Akt group also had an increased percent area of fibrosis compared with the control group (6.61 Ϯ 1.02% vs. 0.18 Ϯ 0.27%, P ϭ 0.003). C: immunohistochemical staining with CD11b antibody showed that the more engrafted fibroblasts that remained, the more inflammatory cells that infiltrated around them.
ments to quantify cell engraftment and trace the cell's fate. In addition, a canine model was used to investigate whether the necrosis inhibition has potentially important clinical implications. In the pilot study using six mice (2 mice/ group), four mice died immediately after cell injection (1 mouse in the control group, 1 mouse in the NI group, and 2 mice in the Akt group). Because fibrillation of the heart developed as soon as the cultured fibroblasts with media were injected into the recipient heart and the mice died, we thought that it was closely related to a toxic effect of the media. After the media were replaced from DMEM-highglucose media to PBS media before cell injection, the mice did not die anymore. In the canine model, there were no complications, including cardiac arrhythmias and death. The results of the present study showed that the transplanted fibroblasts pretreated with NI resulted in focal fibrosis without broad extension or serious complications. Akt activation is known to reduce cell death in part by targeting apoptotic molecules, and it enhances cell survival by increasing intracellular glucose metabolism and energy production under hypoxic conditions (6, 17, 28) . Akt activation also has a variety of paracrine effects, such as enhancing cellular migration and vasculogenesis, which might influence cell survival and fibrosis (9, 18) . Akt is a representative prosurvival factor; the multifactorial effects observed in this study showed that NI was as effective as Akt overexpression in regard to cellular engraftment, resulting in fibrosis and conduction delay. Although Akt overexpression also created fibrosis and conduction delay, its clinical application might be limited by concern in regard to viral cytotoxicity and immunogenesis, resulting in significant negative inotropic and arrhythmogenic adverse effects (27) .
Although the therapeutic application of cell therapy has been widely investigated in many fields, such as cosmetics, stem cell biology, and cardiovascular abnormalities (22, 31) , limited engraftment remains a major problem. The present study demonstrated that increased cell engraftment by reducing cell death can be achieved by survival factor priming, which can potentially enhance the efficiency of cell therapy.
Radiofrequency catheter ablation is a well-established nonpharmacological modality used for the treatment of arrhythmias. Although radiofrequency catheter ablation is widely used, the ablation success rates are much lower in arrhythmias involving thick myocardial areas such as ventricular arrhythmias (2) . Therefore, it is necessary to develop a new method that can effectively create a transmural lesion for the control of arrhythmias. According to our data, delivery of fibroblasts primed with survival factors might be a promising approach for the study of conduction modification of the heart, which could have significant implications for the treatment and management of arrhythmias.
In conclusion, fibroblast injections with survival factor priming increased cellular engraftment after transplantation and induced effective conduction delay in vivo. These results suggest that an effective strategy for cellular engraftment and a promising approach for cell therapy would be survival factor priming. 
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